The Effect of Gastric Bypass Surgery on Diabetes

Status Completed

Clinical Trial Summary

This study will investigate the effects of gastric bypass surgery on type II diabetes. The study will recruit patients with type II diabetes having Roux-en-Y gastric bypass, patients without type II diabetes having Roux-en-Y gastric bypass, and control subjects (patients having gastroscopy, but no surgery). Targeted enrollment is 30 patients per group. Samples of intestine are taken prior to surgery in gastroscopy, during surgery, and 6 months after surgery during gastroscopy. Meal test with incretin measurements, and feces and blood samplings are performed before and after surgery

Hypotheses are:

- The pathogenesis of type II diabetes is linked to changes in the expression of intestinal endocrine cells

- The changes in the incretine excretion after the gastric bypass surgery partly explain the amelioration of type II diabetes

- The oxidation of lipoprotein is diminished after the gastric bypass surgery slowing the development of atherosclerosis

- The immunologic functions of the intestine are changed by the gastric bypass surgery attenuating systemic inflammation

- The gastric bypass surgery changes cholesterol and bile acid metabolism

- The gastric bypass surgery changes the fecal microbiota

Primary end points are:

- Changes in the amounts of endocrine cells in ventricle, duodenum and jejunum

- Changes in the incretine secretion studied with liquid meal test

- Changes in the oxidation of lipoproteins

- Changes in the immunologic markers in ventricle, duodenum and jejunum

- Changes in the amounts of phytosterols, cholesterol metabolites and bile acids

- Changes in fecal microbiota

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01330251
Study type	Observational
Source	University of Oulu
Contact
Status	Completed
Phase	N/A
Start date	January 2011
Completion date	December 2016

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04569214` - The Efficacy and Safety of PAZ320 on PPG and Insulin Blood Levels in Type II Diabetic Patients	Phase 2
Completed	`NCT02127762` - The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy	N/A
Completed	`NCT01698528` - Evaluation of a Prototype Diabetes Management System Applied to Insulin Initiation and Titration	N/A
Completed	`NCT00985114` - Safety and Efficacy Study of EndoBarrier in Subjects With Type II Diabetes and Obesity	N/A
Active, not recruiting	`NCT05120219` - A Study to Assess the Effect of Food on HR20033 and Pharmacokinetic After Multiple Dose in Healthy Volunteers	Phase 1
Completed	`NCT04893135` - Impact of the Rapid Normalization of Chronic Hyperglycemia and the Practice of Moderate Physical Activity on the "Receptor Activator of Nuclear Factor-kappa B Ligand / Osteoprotégérine (RANKL / OPG) System in Patients Living With Type II Diabetes	N/A
Not yet recruiting	`NCT05108350` - A Study to Assess the Bioequivalence of Fixed Dose Combination of HR20033 Relative to Co-administration of the Individual Components in Healthy Chinese Subjects	Phase 1
Completed	`NCT02586129` - Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes	Phase 3
Completed	`NCT02914743` - Providing Preventive Periodontal Treatment to Hospitalized Patients With Diabetes	N/A
Completed	`NCT04540016` - Mass Balance and Biotransformation of [14C]HSK7653 in Human	Phase 1
Completed	`NCT02429258` - Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin	Phase 4
Completed	`NCT01055223` - Fracture Risk With Thiazolidinediones	N/A
Terminated	`NCT02365233` - Fatty Liver Study in Patients With Type II Diabetes	Phase 4
Completed	`NCT05878587` - Burger Allen Exercises in Knee OA With Type II Diabetes	N/A
Completed	`NCT04768673` - A Study to Investigate the PK and Safety of CKD-393	Phase 1
Not yet recruiting	`NCT05028140` - Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus	Phase 3
Terminated	`NCT01804777` - Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes	Early Phase 1
Completed	`NCT01619332` - Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763	Phase 1/Phase 2
Active, not recruiting	`NCT06387433` - Effectiveness of an mHealth Mobile App	N/A
Not yet recruiting	`NCT01591525` - Diabetes Mellitus Community Based Screening in Minority Populations	N/A